A case is described of fatal haemorrhagic varicella zoster in a steroid dependent asthmatic patient concurrently receiving methotrexate. The future management of patients on immunosuppressive steroid sparing drugs is discussed. (Thorax 1995;50:1221-1222 Keywords: asthma, varicella zoster, immunosuppression.
sound scan were unhelpful. The pain persisted and, following the development of pyrexia, he was started on intravenous cefuroxime 750 mg three times a day.
On the third day a non-itchy vesicular rash was evident mainly on the trunk and skin creases. Some of the vesicular lesions were necrotic and haemorrhagic. Immunofluorescence of fluid aspirated from the vesicles was positive for varicella zoster and acyclovir was started at 10 mg/kg intravenously eight hourly. A clotting screen was markedly abnormal with a KCCT of >200 seconds (normal 26-37), thrombin time of >60 seconds (control 12), prothrombin time of 48-4 seconds (control 12-15) , and a fibrinogen level of <0 1 g/l (normal 1-6-3-9). Indeed, no coagulation was seen with conventional assays. The platelet count was 63 x 109/l. Disseminated intravascular coagulation was diagnosed and, despite intensive support, he arrested and died four hours later. Necroscopic examinations revealed foci of haemorrhagic necrosis in the pancreas and liver. The varicella zoster antibody screen was negative, proving that this was disseminated varicella zoster infection and not disseminated zoster.
A 33 year old steroid dependent asthmatic man presented with a three day history of lower chest epigastric pain with intermittent radiation through to the back. He had been maintained on systemic steroids for the past 14 years (prednisolone 2 5-20 mg/day or triamcinolone 40-80 mg intramuscularly at 4-6 week intervals). Three years before presentation he had been started on methotrexate at a dose of 15 mg/week which had led to an improvement in his asthma and allowed his maintenance dose of prednisolone to be decreased. There was no biochemical or haematological evidence of an adverse reaction at the bimonthly follow up visits. Whilst on methotrexate his usual maintenance dose of prednisolone was 7-5-12-5 mg/day. In the year before admission he had required five booster courses of prednisolone, and in the two days before admission he had increased the dose of prednisolone to 50 mg/day and continued on theophylline 1 -2 g/ day with bronchodilators and steroid inhalers. On direct questioning the patient stated that five weeks earlier his daughter had developed chickenpox and that he had had the illness as a child.
On examination he was apyrexial, cushingoid, and had obvious pain. He had a scaly, erythematous, macular papular rash, mainly in the skin creases (groins, axilla, and neck) resulting from a chronic tinea infection which was noted to have increased in severity. He was otherwise normal apart from a tachycardia of 100 beats/min.
Investigations revealed a raised white cell count of 13-3 x 109/1 (neutrophils 11-65, of symptoms, and the late onset ofthe vesicular rash. As a result of our experience in this case we recommend that varicella zoster antibodies should be measured in all patients receiving methotrexate and, if the result is negative, patients should be advised to seek medical attention when there is contact with chickenpox so that passive immunisation with varicella zoster immunoglobulins can be given.
Active immunisation with varicella vaccine is available at present in the UK on a named patient basis. Trials with the vaccine have been performed in healthy adults and in healthy children and those suffering from leukaemia. More than 95% ofhealthy children seroconvert following vaccination, and more than 90% are fully protected on subsequent exposure to the virus. In children with leukaemia two doses were required to induce seroconversion in 90%, with a protection rate of 85%. In healthy adults seroconversion was harder to achieve and there was a lower protection rate of 70%.67 Protection ofimmunosuppressed adults may therefore be harder to achieve and, at present, active vaccination cannot be recommended. Increased awareness, prevention of exposure, passive immunisation, and antiviral therapy are all required in the management of this complication of immunosuppression. 
